Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus irinotecan in refractory metastatic colorectal cancer with KRAS mutation
2012-000644-94Phase 2Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sorafenib in metastatic colon cancer (mCRC) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Progression-free survival. Started Sep 2012; status: active.
02
Drugs
sorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2012-000644-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000644-94.